Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

• DOI: 10.3389/fped.2024.1404725
• Publication Date: 2024-07-31T04:42:38Z
• Authors: Xin Wei; Xinzhu Liu; Yingying Yu; Wei Xie; Wentao Luo; Ye Tu; Shuhong Bu; Guimei Guo
• Keywords: Eculizumab; Complement

Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is therapeutic agent utilized in treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting terminal complex C5b-9. In pediatric patient with aHUS 14 months, administration eculizumab therapy was accompanied inclusion meningococcal vaccine as part national immunization program. Notably, no other antibiotics were administered prior to or during course treatment. Moreover, there occurrences infusion reactions infections observed throughout Due presence anti-factor H antibodies and insufficient recovery, glucocorticoids at week 0 1, followed initiation mycophenolate mofetil (MMF) dosage 250 mg (approximately 548 mg/m 2 ) per day starting from Day 10. recovered after 8 doses eculizumab, interval extended once every 3 weeks month since 9th administration. We experienced successfully treated rare case 14-month-old Chinese patient.